Jutta Bergler-Klein, Associate University Professor and Senior Physician (Oberarzt) in Cardiology, Head of the Cardiac Outpatients Clinic, Specializing in Cardio-Oncology, shared a post on LinkedIn about a recent article she and colleagues authored:
“Troponin and cardiac serum biomarkers can be helpful to predict cardiac risk also during therapy for chronic lymphocytic leukemia (CLL) and other hematologic neoplasms.”
Title: Changes in cardiac parameters during venetoclax treatment
Authors: Roman Brock, Edit Porpaczy, Patrick Caron, Cathrin Skrabs, Renate Thalhammer, Olga Falco, Ingrid Simonitsch-Klupp, Ana-Iris Schiefer, Wolfgang R. Sperr, Karoline V. Gleixner, Martina Schlager, Peter Valent, Raute Sunder-Plassmann, Jutta Bergler-Klein, Katrina Vanura, Chantal Guillemette, Philipp Staber, Ulrich Jäger
Read the Full Article in haemotologica.
More posts featuring Venetoclax on OncoDaily.